Breakout Sessions : The New World of Life Sciences M&A Valuation: Strategies to Adapt and Thrive

jun 4, 2019: 11 a.m. - 12:15 p.m.
109AB, Level 100

In recent years, there%u2019s been a scarcity of high quality, revenue-generating biopharma assets. This dearth, coupled with larger pharma%u2019s growth requirements, has led to a significant run up in valuations of private and public biotech assets. As a result, organizations have been forced to adopt new and more advanced valuation techniques to appropriately evaluate acquisition targets. Representatives from the industry%u2019s most successful pharma/biotech organizations will share insights and best practices for capturing and analyzing the most relevant aspects in designing a comprehensive valuation for M&A and what challenges remain.

Speakers

Douglas Giordano
Senior VP, Worldwide B...

John Babitt
Partner

John Fowler
Vice Chairman of Healt...

Evan Lippman
Head of Corporate Deve...

Joshua Schafer
SVP, Business Developm...